Can the new cervical cancer screening and management guidelines be simplified?

JAMA Internal Medicine

Volumn 174, Issue 7, 2014, Pages 1029-1030

  Feldman, Sarah ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RISK; CANCER SCREENING; CLINICAL PRACTICE; COST; HUMAN; PAPANICOLAOU TEST; PATIENT CARE; PATIENT PREFERENCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; SHORT SURVEY; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; WART VIRUS;

FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; PRACTICE GUIDELINES AS TOPIC; UTERINE CERVICAL NEOPLASMS;

EID: 84904119249     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.576     Document Type: Short Survey

References (9)

1. Moyer VA; U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement [published correction appears in Ann Intern Med. 2013;158(11):852]. Ann Intern Med. 2012;156(12):880-891, W312.
2. Saslow D, Solomon D, Lawson HW, et al ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62(3):147-172.
3. Feldman S. Making sense of the new cervical-cancer screening guidelines. N Engl J Med. 2011;365(23):2145-2147.
4. Massad LS, Einstein MH, Huh WK, et al; 2012 ASCCP Consensus Guidelines Conference. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol. 2013;121(4):829-846.
5. Smith-McCune K. Choosing a screening method for cervical cancer: Papanicolaou testing alone or with human papillomavirus testing [published online May 5, 2014]. JAMA Intern Med. doi:10.1001/jamainternmed.2014.1368.
6. Katki HA, Gage JC, Schiffman M, et al. Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less. J Low Genit Tract Dis. 2013;17(5)(suppl 1):S69-S77.
7. Katki HA, Schiffman M, Castle PE, et al. Five-year risks of CIN 3+ and cervical cancer among women with HPV-positive and HPV-negative high-grade Pap results. J Low Genit Tract Dis. 2013;17(5)(suppl 1):S50-S55.
8. Castle PE, Fetterman B, Poitras N, et al. Variable risk of cervical precancer and cancer after a human papillomavirus-positive test. Obstet Gynecol. 2011;117(3):650-656.
9. Melnikow J, Kulasingam S, Slee C, et al. Surveillance after treatment for cervical intraepithelial neoplasia: outcomes, costs, and cost-effectiveness. Obstet Gynecol. 2010;116(5):1158-1170.